AML 0 3 0 3 B-cancer
( 4 5 4 5 O
Arm 5 8 5 8 O
B 9 10 9 10 O
): 10 12 10 12 O
Relapsed 13 21 13 21 O
/ 21 22 21 22 O
refractory 22 32 22 32 O
/ 32 33 32 33 O
unable 33 39 33 39 O
to 40 42 40 42 O
tolerate 43 51 43 51 O
conventional 52 64 52 64 O
chemotherapy 65 77 65 77 B-treatment

As 0 2 78 80 O
of 3 5 81 83 O
July 6 10 84 88 O
2018 11 15 89 93 O
, 15 16 93 94 O
only 17 21 95 99 O
high 22 26 100 104 O
risk 27 31 105 109 O
MDS 32 35 110 113 B-chronic_disease
patients 36 44 114 122 O
will 45 49 123 127 O
be 50 52 128 130 O
eligible 53 61 131 139 O
as 62 64 140 142 O
Arm 65 68 143 146 O
B 69 70 147 148 O
is 71 73 149 151 O
closed 74 80 152 158 O
. 80 81 158 159 O
As 82 84 160 162 O
of 85 87 163 165 O
October 88 95 166 173 O
2017 96 100 174 178 O
, 100 101 178 179 O
those 102 107 180 185 O
patients 108 116 186 194 O
with 117 121 195 199 O
MDS 122 125 200 203 O
who 126 129 204 207 O
have 130 134 208 212 O
received 135 143 213 221 O
prior 144 149 222 227 B-treatment
treatment 150 159 228 237 I-treatment
will 160 164 238 242 O
now 165 168 243 246 O
be 169 171 247 249 O
enrolled 172 180 250 258 O
in 181 183 259 261 O
Arm 184 187 262 265 O
A 188 189 266 267 O
as 190 192 268 270 O
Arm 193 196 271 274 O
C 197 198 275 276 O
is 199 201 277 279 O
closed 202 208 280 286 O

Carbamazepine 0 13 287 300 B-treatment
( 14 15 301 302 O
e.g. 15 19 302 306 O
Tegretol 20 28 307 315 B-treatment
) 28 29 315 316 O

Clarithromycin 0 14 317 331 B-treatment
( 15 16 332 333 O
e.g. 16 20 333 337 O
Biaxin 21 27 338 344 B-treatment
) 27 28 344 345 O

Cyclosporin 0 11 346 357 B-treatment
e.g. 12 16 358 362 O
( 17 18 363 364 O
Neoral 18 24 364 370 B-treatment
or 25 27 371 373 O
Sandimmune 28 38 374 384 B-treatment
) 38 39 384 385 O

Diltiazem 0 9 386 395 B-treatment
( 10 11 396 397 O
e.g. 11 15 397 401 O
Cardizem 16 24 402 410 B-treatment
) 24 25 410 411 O

Erythromycin 0 12 412 424 B-treatment
( 13 14 425 426 O
e.g. 14 18 426 430 O
Akne 19 23 431 435 B-treatment
- 23 24 435 436 I-treatment
Mycin 24 29 436 441 I-treatment
, 29 30 441 442 O
Ery 31 34 443 446 B-treatment
- 34 35 446 447 I-treatment
Tab 35 38 447 450 I-treatment
) 38 39 450 451 O

Fluconazole 0 11 452 463 B-treatment
( 12 13 464 465 O
e.g. 13 17 465 469 O
Diflucan 18 26 470 478 B-treatment
) 26 27 478 479 O

Intrathecal 0 11 480 491 B-treatment
ARA 12 15 492 495 I-treatment
- 15 16 495 496 I-treatment
C 16 17 496 497 I-treatment
and 18 21 498 501 O
intrathecal 22 33 502 513 B-treatment
methotrexate 34 46 514 526 I-treatment
are 47 50 527 530 O
permissible 51 62 531 542 O
( 63 64 543 544 O
as 64 66 544 546 O
they 67 71 547 551 O
are 72 75 552 555 O
not 76 79 556 559 O
systemic 80 88 560 568 O
and 89 92 569 572 O
only 93 97 573 577 O
isolated 98 106 578 586 O
to 107 109 587 589 O
the 110 113 590 593 O
central 114 121 594 601 O
nervous 122 129 602 609 O
system 130 136 610 616 O
) 136 137 616 617 O

Itraconazole 0 12 618 630 B-treatment
( 13 14 631 632 O
e.g. 14 18 632 636 O
Sporanox 19 27 637 645 B-treatment
) 27 28 645 646 O

Ketoconazole 0 12 647 659 B-treatment
( 13 14 660 661 O
e.g. 14 18 661 665 O
Nizoral 19 26 666 673 B-treatment
) 26 27 673 674 O

MDS 0 3 675 678 B-cancer
( 4 5 679 680 I-cancer
Arm 5 8 680 683 I-cancer
A 9 10 684 685 I-cancer
): 10 12 685 687 I-cancer
High 13 17 688 692 O
- 17 18 692 693 O
risk 18 22 693 697 O
MDS 23 26 698 701 O
defined 27 34 702 709 O
as 35 37 710 712 O
: 37 38 712 713 O
> 39 40 714 715 O
5 40 41 715 716 B-lower_bound
% 41 42 716 717 I-lower_bound
blasts 43 49 718 724 O
in 50 52 725 727 O
bone 53 57 728 732 O
marrow 58 64 733 739 O
and/or 65 71 740 746 O
the 72 75 747 750 O
following 76 85 751 760 O
cytogenetic 86 97 761 772 O
categories 98 108 773 783 O
: 108 109 783 784 O
presence 110 118 785 793 O
of 119 121 794 796 O
inv(3)/t(3q)/del(3q 122 141 797 816 O
) 141 142 816 817 O
, 142 143 817 818 O
-7 144 146 819 821 O
/ 146 147 821 822 O
del(7q 147 153 822 828 O
) 153 154 828 829 O
, 154 155 829 830 O
complex 156 163 831 838 O
cytogenetics 164 176 839 851 O
( 177 178 852 853 O
3 178 179 853 854 O
or 180 182 855 857 O
more 183 187 858 862 O
abnormalities 188 201 863 876 O
) 201 202 876 877 O

MDS 0 3 878 881 B-cancer
or 4 6 882 884 O
AML 7 10 885 888 B-cancer
as 11 13 889 891 O
above 14 19 892 897 O
BUT 20 23 898 901 O
with 24 28 902 906 O
prior 29 34 907 912 B-treatment
therapy 35 42 913 920 I-treatment
with 43 47 921 925 I-treatment
Azacitibine 48 59 926 937 I-treatment
( 60 61 938 939 O
Arm 61 64 939 942 O
C 65 66 943 944 O
): 66 68 944 946 O
Patients 69 77 947 955 O
who 78 81 956 959 O
meet 82 86 960 964 O
criteria 87 95 965 973 O
for 96 99 974 977 O
either 100 106 978 984 O
Arm 107 110 985 988 O
A 111 112 989 990 O
or 113 115 991 993 O
Arm 116 119 994 997 O
B 120 121 998 999 O
but 122 125 1000 1003 O
have 126 130 1004 1008 O
been 131 135 1009 1013 O
treated 136 143 1014 1021 O
or 144 146 1022 1024 O
are 147 150 1025 1028 O
currently 151 160 1029 1038 O
treated 161 168 1039 1046 O
with 169 173 1047 1051 O
Azacitibine 174 185 1052 1063 O

Patient 0 7 1064 1071 O
may 8 11 1072 1075 O
have 12 16 1076 1080 O
previously 17 27 1081 1091 O
had 28 31 1092 1095 O
azacitidine 32 43 1096 1107 B-treatment
or 44 46 1108 1110 O
decitabine 47 57 1111 1121 B-treatment
will 58 62 1122 1126 O
be 63 65 1127 1129 O
eligible 66 74 1130 1138 O
to 75 77 1139 1141 O
enroll 78 84 1142 1148 O
on 85 87 1149 1151 O
Arm 88 91 1152 1155 O
A 92 93 1156 1157 O
( 94 95 1158 1159 O
MDS 95 98 1159 1162 B-chronic_disease
) 98 99 1162 1163 O

Patients 0 8 1164 1172 O
can 9 12 1173 1176 O
not 13 16 1177 1180 O
have 17 21 1181 1185 O
received 22 30 1186 1194 O
more 31 35 1195 1199 O
than 36 40 1200 1204 O
3 41 42 1205 1206 B-lower_bound
prior 43 48 1207 1212 I-lower_bound
lines 49 54 1213 1218 O
of 55 57 1219 1221 O
therapy 58 65 1222 1229 B-treatment
for 66 69 1230 1233 O
their 70 75 1234 1239 O
hematologic 76 87 1240 1251 B-cancer
malignancy 88 98 1252 1262 I-cancer

Patients 0 8 1263 1271 O
may 9 12 1272 1275 O
have 13 17 1276 1280 O
had 18 21 1281 1284 O
a 22 23 1285 1286 O
prior 24 29 1287 1292 B-treatment
stem 30 34 1293 1297 I-treatment
cell 35 39 1298 1302 I-treatment
transplant 40 50 1303 1313 I-treatment
( 51 52 1314 1315 I-treatment
autologous 52 62 1315 1325 I-treatment
or 63 65 1326 1328 I-treatment
allogeneic 66 76 1329 1339 I-treatment
) 76 77 1339 1340 I-treatment
, 77 78 1340 1341 O
however 79 86 1342 1349 O
they 87 91 1350 1354 O
may 92 95 1355 1358 O
not 96 99 1359 1362 O
have 100 104 1363 1367 O
active 105 111 1368 1374 O
GvHD 112 116 1375 1379 B-chronic_disease
, 116 117 1379 1380 O
nor 118 121 1381 1384 O
be 122 124 1385 1387 O
on 125 127 1388 1390 O
any 128 131 1391 1394 O
immunosuppression 132 149 1395 1412 B-treatment

Patients 0 8 1413 1421 O
must 9 13 1422 1426 O
be 14 16 1427 1429 O
able 17 21 1430 1434 O
to 22 24 1435 1437 O
consume 25 32 1438 1445 O
oral 33 37 1446 1450 B-treatment
medication 38 48 1451 1461 I-treatment

Patients 0 8 1462 1470 O
must 9 13 1471 1475 O
be 14 16 1476 1478 O
able 17 21 1479 1483 O
to 22 24 1484 1486 O
sign 25 29 1487 1491 O
consent 30 37 1492 1499 O
and 38 41 1500 1503 O
be 42 44 1504 1506 O
willing 45 52 1507 1514 O
and 53 56 1515 1518 O
able 57 61 1519 1523 O
to 62 64 1524 1526 O
comply 65 71 1527 1533 O
with 72 76 1534 1538 O
scheduled 77 86 1539 1548 O
visits 87 93 1549 1555 O
, 93 94 1555 1556 O
treatment 95 104 1557 1566 B-treatment
plan 105 109 1567 1571 O
and 110 113 1572 1575 O
laboratory 114 124 1576 1586 O
testing 125 132 1587 1594 O

Patients 0 8 1595 1603 O
must 9 13 1604 1608 O
be 14 16 1609 1611 O
â‰¥ 17 18 1612 1613 O
18 19 21 1614 1616 B-lower_bound
years 22 27 1617 1622 I-lower_bound
old 28 31 1623 1626 O

Patients 0 8 1627 1635 O
must 9 13 1636 1640 O
have 14 18 1641 1645 O
a 19 20 1646 1647 O
life 21 25 1648 1652 B-clinical_variable
expectancy 26 36 1653 1663 I-clinical_variable
of 37 39 1664 1666 O
at 40 42 1667 1669 O
least 43 48 1670 1675 O
4 49 50 1676 1677 B-lower_bound
weeks 51 56 1678 1683 I-lower_bound

Patients 0 8 1684 1692 O
must 9 13 1693 1697 O
have 14 18 1698 1702 O
an 19 21 1703 1705 O
ECOG 22 26 1706 1710 B-clinical_variable
performance 27 38 1711 1722 I-clinical_variable
status 39 45 1723 1729 I-clinical_variable
of 46 48 1730 1732 O
< 49 50 1733 1734 O
= 50 51 1734 1735 O
2 52 53 1736 1737 B-lower_bound

Patients 0 8 1738 1746 O
must 9 13 1747 1751 O
have 14 18 1752 1756 O
completed 19 28 1757 1766 O
any 29 32 1767 1770 O
radiotherapy 33 45 1771 1783 B-treatment
four 46 50 1784 1788 B-upper_bound
weeks 51 56 1789 1794 I-upper_bound
prior 57 62 1795 1800 I-upper_bound
to 63 65 1801 1803 O
study 66 71 1804 1809 O
entry 72 77 1810 1815 O
, 77 78 1815 1816 O
0 79 80 1817 1818 B-lower_bound
- 80 81 1818 1819 O
2 81 82 1819 1820 B-upper_bound
weeks 83 88 1821 1826 I-upper_bound
for 89 92 1827 1830 O
local 93 98 1831 1836 O
palliative 99 109 1837 1847 B-treatment
XRT 110 113 1848 1851 I-treatment
( 114 115 1852 1853 O
small 115 120 1853 1858 O
port 121 125 1859 1863 O
) 125 126 1863 1864 O

Patients 0 8 1865 1873 O
must 9 13 1874 1878 O
have 14 18 1879 1883 O
recovered 19 28 1884 1893 O
from 29 33 1894 1898 O
the 34 37 1899 1902 O
toxic 38 43 1903 1908 O
effects 44 51 1909 1916 O
of 52 54 1917 1919 O
any 55 58 1920 1923 O
prior 59 64 1924 1929 B-treatment
chemotherapy 65 77 1930 1942 I-treatment
to 78 80 1943 1945 O
< 81 82 1946 1947 O
Grade 83 88 1948 1953 B-upper_bound
2 89 90 1954 1955 I-upper_bound
( 91 92 1956 1957 O
except 92 98 1957 1963 O
for 99 102 1964 1967 O
alopecia 103 111 1968 1976 B-chronic_disease
) 111 112 1976 1977 O

Patients 0 8 1978 1986 O
must 9 13 1987 1991 O
not 14 17 1992 1995 O
be 18 20 1996 1998 O
pregnant 21 29 1999 2007 B-pregnancy
or 30 32 2008 2010 O
breastfeeding 33 46 2011 2024 O

Patients 0 8 2025 2033 O
must 9 13 2034 2038 O
not 14 17 2039 2042 O
be 18 20 2043 2045 O
receiving 21 30 2046 2055 O
any 31 34 2056 2059 O
chemotherapy 35 47 2060 2072 B-treatment
agents 48 54 2073 2079 I-treatment
( 55 56 2080 2081 O
except 56 62 2081 2087 O
Hydroxyurea 63 74 2088 2099 B-treatment
) 74 75 2099 2100 O

Patients 0 8 2101 2109 O
must 9 13 2110 2114 O
not 14 17 2115 2118 O
have 18 22 2119 2123 O
received 23 31 2124 2132 O
any 32 35 2133 2136 O
investigational 36 51 2137 2152 B-treatment
agents 52 58 2153 2159 I-treatment
within 59 65 2160 2166 O
21days 66 72 2167 2173 B-upper_bound
of 73 75 2174 2176 O
study 76 81 2177 2182 O
entry 82 87 2183 2188 O

Patients 0 8 2189 2197 O
who 9 12 2198 2201 O
have 13 17 2202 2206 O
uncontrolled 18 30 2207 2219 B-chronic_disease
infection 31 40 2220 2229 I-chronic_disease
are 41 44 2230 2233 O
not 45 48 2234 2237 O
eligible 49 57 2238 2246 O
. 57 58 2246 2247 O
Patients 59 67 2248 2256 O
must 68 72 2257 2261 O
have 73 77 2262 2266 O
any 78 81 2267 2270 O
active 82 88 2271 2277 B-chronic_disease
infections 89 99 2278 2288 I-chronic_disease
under 100 105 2289 2294 O
control 106 113 2295 2302 O
. 113 114 2302 2303 O
Fungal 115 121 2304 2310 B-chronic_disease
disease 122 129 2311 2318 I-chronic_disease
must 130 134 2319 2323 O
be 135 137 2324 2326 O
stable 138 144 2327 2333 O
for 145 148 2334 2337 O
at 149 151 2338 2340 O
least 152 157 2341 2346 O
2 158 159 2347 2348 B-lower_bound
weeks 160 165 2349 2354 I-lower_bound
before 166 172 2355 2361 I-lower_bound
study 173 178 2362 2367 O
entry 179 184 2368 2373 O
. 184 185 2373 2374 O
Patients 186 194 2375 2383 O
with 195 199 2384 2388 O
bacteremia 200 210 2389 2399 B-chronic_disease
must 211 215 2400 2404 O
have 216 220 2405 2409 O
documented 221 231 2410 2420 O
negative 232 240 2421 2429 O
blood 241 246 2430 2435 O
cultures 247 255 2436 2444 O
prior 256 261 2445 2450 O
to 262 264 2451 2453 O
study 265 270 2454 2459 O
entry 271 276 2460 2465 O

Patients 0 8 2466 2474 O
with 9 13 2475 2479 O
known 14 19 2480 2485 O
HIV 20 23 2486 2489 B-chronic_disease
positivity 24 34 2490 2500 O
or 35 37 2501 2503 O
AIDS 38 42 2504 2508 B-chronic_disease
- 42 43 2508 2509 I-chronic_disease
related 43 50 2509 2516 I-chronic_disease
illness 51 58 2517 2524 I-chronic_disease

Patients 0 8 2525 2533 O
with 9 13 2534 2538 O
uncontrolled 14 26 2539 2551 B-chronic_disease
high 27 31 2552 2556 I-chronic_disease
blood 32 37 2557 2562 I-chronic_disease
pressure 38 46 2563 2571 I-chronic_disease
, 46 47 2571 2572 O
unstable 48 56 2573 2581 B-chronic_disease
angina 57 63 2582 2588 I-chronic_disease
, 63 64 2588 2589 O
symptomatic 65 76 2590 2601 O
congestive 77 87 2602 2612 B-chronic_disease
heart 88 93 2613 2618 I-chronic_disease
failure 94 101 2619 2626 I-chronic_disease
, 101 102 2626 2627 O
myocardial 103 113 2628 2638 B-chronic_disease
infarction 114 124 2639 2649 I-chronic_disease
within 125 131 2650 2656 O
the 132 135 2657 2660 O
past 136 140 2661 2665 B-upper_bound
6 141 142 2666 2667 I-upper_bound
months 143 149 2668 2674 I-upper_bound
or 150 152 2675 2677 O
serious 153 160 2678 2685 O
uncontrolled 161 173 2686 2698 O
cardiac 174 181 2699 2706 B-chronic_disease
arrhythmia 182 192 2707 2717 I-chronic_disease

Pregnancy 0 9 2718 2727 B-pregnancy
tests 10 15 2728 2733 O
must 16 20 2734 2738 O
be 21 23 2739 2741 O
obtained 24 32 2742 2750 O
for 33 36 2751 2754 O
all 37 40 2755 2758 O
females 41 48 2759 2766 B-gender
of 49 51 2767 2769 O
child 52 57 2770 2775 O
- 57 58 2775 2776 O
bearing 58 65 2776 2783 O
potential 66 75 2784 2793 O

Pregnant 0 8 2794 2802 B-pregnancy
or 9 11 2803 2805 O
lactating 12 21 2806 2815 O
patients 22 30 2816 2824 O
are 31 34 2825 2828 O
ineligible 35 45 2829 2839 O
for 46 49 2840 2843 O
this 50 54 2844 2848 O
study 55 60 2849 2854 O
due 61 64 2855 2858 O
to 65 67 2859 2861 O
the 68 71 2862 2865 O
unknown 72 79 2866 2873 O
human 80 85 2874 2879 O
fetal 86 91 2880 2885 O
or 92 94 2886 2888 O
teratogenic 95 106 2889 2900 O
toxicities 107 117 2901 2911 O
of 118 120 2912 2914 O
rapamycin 121 130 2915 2924 B-treatment

Rifabutin 0 9 2925 2934 B-treatment
( 10 11 2935 2936 O
e.g. 11 15 2936 2940 O
Mycobutin 16 25 2941 2950 B-treatment
) 25 26 2950 2951 O

Rifampin 0 8 2952 2960 B-treatment
( 9 10 2961 2962 O
e.g. 10 14 2962 2966 O
Rifadin 15 22 2967 2974 B-treatment
) 22 23 2974 2975 O

Rifapentine 0 11 2976 2987 B-treatment
( 12 13 2988 2989 O
e.g. 13 17 2989 2993 O
Priftin 18 25 2994 3001 B-treatment
) 25 26 3001 3002 O

St. 0 3 3003 3006 B-treatment
John 4 8 3007 3011 I-treatment
's 8 10 3011 3013 I-treatment
Wort- 11 16 3014 3019 I-treatment
may 17 20 3020 3023 O
decrease 21 29 3024 3032 O
effects 30 37 3033 3040 O
of 38 40 3041 3043 O
sirolimus 41 50 3044 3053 B-treatment
by 51 53 3054 3056 O
decreasing 54 64 3057 3067 O
the 65 68 3068 3071 O
amount 69 75 3072 3078 O
of 76 78 3079 3081 O
sirolimus 79 88 3082 3091 O
in 89 91 3092 3094 O
the 92 95 3095 3098 O
body 96 100 3099 3103 O

Tacrolimus 0 10 3104 3114 B-treatment
( 11 12 3115 3116 O
e.g. 12 16 3116 3120 O
Prograf 17 24 3121 3128 B-treatment
) 24 25 3128 3129 O
- 26 27 3130 3131 O
May 28 31 3132 3135 O
cause 32 37 3136 3141 O
liver 38 43 3142 3147 B-treatment
transplant 44 54 3148 3158 I-treatment
rejection 55 64 3159 3168 O
or 65 67 3169 3171 O
serious 68 75 3172 3179 O
side 76 80 3180 3184 O
effects 81 88 3185 3192 O
in 89 91 3193 3195 O
patients 92 100 3196 3204 O
on 101 103 3205 3207 O
sirolimus 104 113 3208 3217 B-treatment

Telithromycin 0 13 3218 3231 B-treatment
( 14 15 3232 3233 O
e.g. 15 19 3233 3237 O
Ketek 20 25 3238 3243 B-treatment
) 25 26 3243 3244 O

Verapamil 0 9 3245 3254 B-treatment
( 10 11 3255 3256 O
e.g. 11 15 3256 3260 O
Calan 16 21 3261 3266 B-treatment
SR 22 24 3267 3269 I-treatment
, 24 25 3269 3270 O
Isoptin 26 33 3271 3278 B-treatment
, 33 34 3278 3279 O
Verelan 35 42 3280 3287 B-treatment
) 42 43 3287 3288 O

Voriconazole 0 12 3289 3301 B-treatment
( 13 14 3302 3303 O
e.g. 14 18 3303 3307 O
VFEND 19 24 3308 3313 B-treatment
) 24 25 3313 3314 O
- 26 27 3315 3316 O
May 28 31 3317 3320 O
increase 32 40 3321 3329 O
the 41 44 3330 3333 O
effects 45 52 3334 3341 O
of 53 55 3342 3344 O
sirolimus 56 65 3345 3354 B-treatment
by 66 68 3355 3357 O
increasing 69 79 3358 3368 O
the 80 83 3369 3372 O
amount 84 90 3373 3379 O
of 91 93 3380 3382 O
this 94 98 3383 3387 O
medicine 99 107 3388 3396 O
in 108 110 3397 3399 O
the 111 114 3400 3403 O
body 115 119 3404 3408 O
. 119 120 3408 3409 O
Can 121 124 3410 3413 O
take 125 129 3414 3418 O
72 130 132 3419 3421 O
hours 133 138 3422 3427 O
after 139 144 3428 3433 O
last 145 149 3434 3438 O
dose 150 154 3439 3443 O
of 155 157 3444 3446 O
Sirolimus 158 167 3447 3456 B-treatment

